➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Patent: 9,081,016

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,081,016
Title:Assay for measurement of antibodies binding to a therapeutic monoclonal antibody
Abstract: Methods and system for determination of an anti-<therapeutic monoclonal antibody> antibody (anti-<TmAB>AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). Also, methods and systems for the determination of antigen specific antibodies of a particular immunoglobulin class and for the identification of a patient who is at risk of developing an adverse drug reaction (ADR) during treatment with a TmAB.
Inventor(s): Grunert; Veit Peter (Munich, DE), Klause; Ursula (Indianapolis, IN), Kubalec; Pavel (Feldafing, DE), Rothfuss; Matthias (Penzburg, DE), Upmeier; Barbara (Iffeldorf, DE)
Assignee: Roche Diagnostics Operations, Inc. (Indianapolis, IN)
Application Number:13/766,130
Patent Claims:see list of patent claims

Details for Patent 9,081,016

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2030-08-19
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Free Forever Trial 2030-08-19
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Free Forever Trial 2030-08-19
Abbvie Inc. HUMIRA adalimumab Injection 125057 2002-12-31 ⤷  Free Forever Trial 2030-08-19
Abbvie Inc. HUMIRA adalimumab Injection 125057 2008-02-21 ⤷  Free Forever Trial 2030-08-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.